Denosumab for treatment of bone metastases secondary to solid tumours: Systematic review and network meta-analysis
European Journal of Cancer, 08/21/2012
Evidence Based Medicine
Ford JA et al. – Denosumab was found to be more effective in delaying the time to first skeletal related event (SRE) and reducing the risk of first and subsequent SRE compared to zoledronic acid, placebo and pamidronate. In breast and prostate cancer, denosumab was effective in reducing skeletal morbidity rate compared with placebo. The lack of published data on pain and quality of life (QoL) meant that firm conclusions could not be made. Denosumab did not appear to have an affect on overall survival.